Giant Cell Arteritis

Autoimmune MONDO:0008538 Autoimmune Disease Vasculitis

A rare large vessel vasculitis (LVV) characterized by vasculitis predominantly involving the arteries originating from the aortic arch and the extracranial branches of the carotid arteries. Clinical manifestations are variable, the predominant cranial phenotype is characterized by headache, jaw claudication, scalp tenderness and visual symptoms and the predominant LVV type by constitutional symptoms, polymyalgia rheumatica and occasionally limb ischemia. Overlaps between these two phenotypes are common. Most common primary systemic vasculitis in adults over 50.

Ask OpenScientist

Ask a research question about Giant Cell Arteritis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
3
Pathophysiology
0
Histopathology
23
Phenotypes
0
Pathograph
4
Genes
5
Treatments
2
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
13
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
musculoskeletal system disorder connective tissue disease autoimmune disease
◆

Subtypes

2
Cranial Giant Cell Arteritis (C-GCA)
Predominant cranial phenotype characterized by headache, jaw claudication, scalp tenderness, temporal artery abnormalities, and visual symptoms. Higher rates of positive temporal artery biopsy.
Large-Vessel Giant Cell Arteritis (LV-GCA)
Predominant large-vessel phenotype with constitutional symptoms, polymyalgia rheumatica, and involvement of the aorta and its major branches. Patients are generally younger, have longer diagnostic delay, and lower rates of positive temporal artery biopsy.
Show evidence (2 references)
PMID:36858169 SUPPORT Human Clinical
"Patients with LV-GCA were generally younger at diagnosis compared to C-GCA patients (mean age difference -4.53 years), had longer delay to diagnosis (mean difference 3.03 months) and lower rates of positive temporal artery biopsy (OR: 0.52 [95% CI: 0.3, 0.91])."
Systematic review of 46 studies demonstrates LV-GCA as a clinically distinct subtype with younger onset, delayed diagnosis, and lower TAB positivity.
PMID:36858169 SUPPORT Human Clinical
"Fewer LV-GCA patients presented with cranial manifestations and only 53% met the 1990 ACR Classification Criteria for GCA."
LV-GCA patients frequently lack classic cranial symptoms, making diagnosis challenging with traditional criteria.
⚙

Pathophysiology

3
Dendritic Cell Activation in Vessel Wall
Adventitial dendritic cells become activated and produce chemokines that recruit T cells and macrophages. Vascular dendritic cells may sense pathogen-associated or damage-associated molecular patterns.
Dendritic Cell link
Immune Response link
Show evidence (1 reference)
PMID:35629030 SUPPORT
"Once activated, dendritic cells recruit CD4 T cells and induce their activation, proliferation and polarization into Th1 and Th17, which produce interferon-gamma (IFN-γ) and interleukin-17 (IL-17), respectively."
This evidence confirms that dendritic cells are key initiators of the immune response in GCA, recruiting and activating CD4 T cells in the vessel wall.
Th1 and Th17 T Cell Infiltration
CD4+ T cells infiltrate the arterial wall and produce IFN-gamma (Th1) and IL-17 (Th17). IFN-gamma activates macrophages and promotes giant cell formation, while IL-17 drives vascular inflammation.
CD4+ T Cell link Macrophage link
Inflammatory Response link
Show evidence (2 references)
PMID:35629030 PARTIAL
"IFN-γ triggers the production of chemokines by vascular smooth muscle cells, which leads to the recruitment of additional CD4 and CD8 T cells and also monocytes that differentiate into macrophages."
This demonstrates the role of IFN-gamma from Th1 cells in recruiting additional immune cells and promoting macrophage differentiation in the vessel wall.
PMID:36656970 PARTIAL
"Loss of self-tolerance in the adaptive immune system is linked to aberrant signaling in the NOTCH pathway, leading to expansion of NOTCH1+CD4+ T cells and the functional decline of NOTCH4+ T regulatory cells (Checkpoint 1)."
This evidence describes the checkpoint mechanism by which CD4+ T cells become dysregulated through NOTCH signaling, enabling their pathogenic infiltration into the arterial wall.
Giant Cell Formation and Intimal Hyperplasia
Multinucleated giant cells form at the media-intima junction. Smooth muscle cells proliferate causing intimal hyperplasia, leading to vessel stenosis and ischemic complications.
Smooth Muscle Cell link
Cell Proliferation link
Show evidence (2 references)
PMID:36656970 SUPPORT
"Due to the failure of the immuno-inhibitory PD-1 (programmed cell death protein 1)/PD-L1 (programmed cell death ligand 1) pathway, wall-infiltrating immune cells arrive in a permissive tissues microenvironment, where multiple T cell effector lineages thrive, shift toward high glycolytic..."
This describes the immune checkpoint failure that allows multinucleated giant cells to form in the vessel wall through unchecked macrophage activation.
PMID:35629030 SUPPORT
"Under the influence of different mediators, mainly endothelin-1 and PDGF, vascular smooth muscle cells migrate to the intima, proliferate and change their phenotype to become myofibroblasts that further proliferate and produce extracellular matrix proteins, increasing the vascular stenosis."
This evidence explains the mechanism of intimal hyperplasia whereby smooth muscle cells proliferate and produce extracellular matrix, leading to stenosis.
●

Phenotypes

23
Blood 1
Anemia FREQUENT Anemia (HP:0001903)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0001903 | Anemia | Frequent (79-30%)"
Orphanet classifies anemia as frequent in GCA.
Cardiovascular 1
Aortic Dissection OCCASIONAL Aortic dissection (HP:0002647)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0002647 | Aortic dissection | Occasional (29-5%)"
Orphanet classifies aortic dissection as occasional in GCA.
Digestive 1
Anorexia VERY_FREQUENT Anorexia (HP:0002039)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0002039 | Anorexia | Very frequent (99-80%)"
Orphanet classifies anorexia as very frequent in GCA.
Ear 1
Hearing Impairment OCCASIONAL Hearing impairment (HP:0000365)
Show evidence (2 references)
ORPHA:397 SUPPORT
"HP:0000365 | Hearing impairment | Occasional (29-5%)"
Orphanet classifies hearing impairment as occasional in GCA.
PMID:31027087 SUPPORT Human Clinical
"Totally 23 patients (25.3%) had HL."
Chinese cohort of 91 GCA patients found 25.3% had hearing loss.
Eye 2
Visual Impairment FREQUENT Visual impairment (HP:0000505)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0000505 | Visual impairment | Frequent (79-30%)"
Orphanet classifies visual impairment as frequent in GCA.
Diplopia OCCASIONAL Diplopia (HP:0000651)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0000651 | Diplopia | Occasional (29-5%)"
Orphanet classifies diplopia as occasional in GCA.
Integument 1
Alopecia FREQUENT Alopecia (HP:0001596)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0001596 | Alopecia | Frequent (79-30%)"
Orphanet classifies alopecia as frequent in GCA.
Metabolism 1
Fever VERY_FREQUENT Fever (HP:0001945)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0001945 | Fever | Very frequent (99-80%)"
Orphanet classifies fever as very frequent in GCA.
Musculoskeletal 2
Joint Stiffness VERY_FREQUENT Joint stiffness (HP:0001387)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0001387 | Joint stiffness | Very frequent (99-80%)"
Orphanet classifies joint stiffness as very frequent in GCA, reflecting PMR overlap.
Arthritis FREQUENT Arthritis (HP:0001369)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0001369 | Arthritis | Frequent (79-30%)"
Orphanet classifies arthritis as frequent in GCA.
Nervous System 3
Headache VERY_FREQUENT Headache (HP:0002315)
Show evidence (2 references)
ORPHA:397 SUPPORT
"HP:0002315 | Headache | Very frequent (99-80%)"
Orphanet classifies headache as very frequent (99-80%) in GCA.
PMID:38502233 SUPPORT Human Clinical
"Headache was reported by 54 patients (91.5%)."
Monocentric cohort confirms headache in 91.5% of GCA patients.
Depression FREQUENT Depression (HP:0000716)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0000716 | Depression | Frequent (79-30%)"
Orphanet classifies depression as frequent in GCA.
Peripheral Neuropathy OCCASIONAL Peripheral neuropathy (HP:0009830)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0009830 | Peripheral neuropathy | Occasional (29-5%)"
Orphanet classifies peripheral neuropathy as occasional in GCA.
Respiratory 1
Cough OCCASIONAL Cough (HP:0012735)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0012735 | Cough | Occasional (29-5%)"
Orphanet classifies cough as occasional in GCA.
Constitutional 2
Fatigue VERY_FREQUENT Fatigue (HP:0012378)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0012378 | Fatigue | Very frequent (99-80%)"
Orphanet classifies fatigue as very frequent in GCA.
Malaise FREQUENT Malaise (HP:0033834)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0033834 | Malaise | Frequent (79-30%)"
Orphanet classifies malaise as frequent in GCA.
Growth 1
Weight Loss VERY_FREQUENT Weight loss (HP:0001824)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0001824 | Weight loss | Very frequent (99-80%)"
Orphanet classifies weight loss as very frequent in GCA.
Other 6
Jaw Claudication FREQUENT Jaw claudication (HP:0030164)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0030164 | Jaw claudication | Frequent (79-30%)"
Orphanet classifies jaw claudication as frequent in GCA.
Impaired Mastication VERY_FREQUENT Impaired mastication (HP:0005216)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0005216 | Impaired mastication | Very frequent (99-80%)"
Orphanet classifies impaired mastication as very frequent in GCA.
Amaurosis Fugax OCCASIONAL Amaurosis fugax (HP:0100576)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0100576 | Amaurosis fugax | Occasional (29-5%)"
Orphanet classifies amaurosis fugax as occasional in GCA.
Scalp Tenderness OCCASIONAL Scalp tenderness (HP:0100809)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0100809 | Scalp tenderness | Occasional (29-5%)"
Orphanet classifies scalp tenderness as occasional in GCA.
Cerebral Ischemia OCCASIONAL Cerebral ischemia (HP:0002637)
Show evidence (1 reference)
PMID:36858169 PARTIAL Human Clinical
"12% of deaths in LV-GCA patients could be directly attributed to an LV complication."
Systematic review shows LV complications (including cerebrovascular) cause a minority of deaths, consistent with occasional rather than very frequent cerebral ischemia.
Ophthalmoparesis FREQUENT Ophthalmoparesis (HP:0000597)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0000597 | Ophthalmoparesis | Frequent (79-30%)"
Orphanet classifies ophthalmoparesis as frequent in GCA.
🧬

Genetic Associations

4
HLA-DRB1 (Risk Factor)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HLA-DRB1 | major histocompatibility complex, class II, DR beta 1 | hgnc:4948 | Major susceptibility factor in"
Orphanet identifies HLA-DRB1 as a major susceptibility gene for GCA.
HLA-B (Risk Factor)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HLA-B | major histocompatibility complex, class I, B | hgnc:4932 | Major susceptibility factor in"
Orphanet identifies HLA-B as a major susceptibility gene for GCA.
PTPN22 (Risk Factor)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"PTPN22 | protein tyrosine phosphatase non-receptor type 22 | hgnc:9652 | Major susceptibility factor in"
Orphanet identifies PTPN22 as a major susceptibility gene for GCA.
P4HA2 (Risk Factor)
Show evidence (1 reference)
ORPHA:397 SUPPORT
"P4HA2 | prolyl 4-hydroxylase subunit alpha 2 | hgnc:8547 | Major susceptibility factor in"
Orphanet identifies P4HA2 as a major susceptibility gene for GCA.
💊

Treatments

5
High-Dose Corticosteroids
Action: pharmacotherapy MAXO:0000058
Agent: prednisolone ↗
First-line therapy; prompt treatment prevents blindness. Prednisolone is the standard agent, with high cumulative doses typically required.
Show evidence (2 references)
PMID:38502233 SUPPORT Human Clinical
"All received glucocorticoids for 13.1 ± 10 months."
Cohort confirms universal glucocorticoid use as first-line treatment.
PMID:25132663 SUPPORT Human Clinical
"Of the 4,671 patients, 4,655 (99.7%) were prescribed prednisolone."
UK dataset shows near-universal prednisolone use in GCA.
Tocilizumab
Action: pharmacotherapy MAXO:0000058
Agent: tocilizumab ↗
IL-6 receptor inhibitor for steroid-sparing.
Show evidence (2 references)
PMID:37321636 SUPPORT
"Relapse rate prior to TCZ start (0.84 relapses/person-year) was 3-fold reduced while on TCZ (0.28 relapses/person-year; P < 0.001) but increased to 0.64 relapses/person-year after TCZ discontinuation."
This demonstrates tocilizumab's effectiveness in reducing relapse rates while on treatment, though relapse risk increases after discontinuation.
PMID:37321636 PARTIAL
"TCZ is well tolerated in GCA, with low rates of discontinuation for AESIs. However, relapse occurred in > 50% despite median treatment > 12 months."
This provides evidence for tocilizumab's safety profile and highlights the challenge of relapses even with prolonged treatment.
Methotrexate
Action: pharmacotherapy MAXO:0000058
Agent: methotrexate ↗
Steroid-sparing immunosuppressive agent that may allow corticosteroid dose reduction.
Show evidence (1 reference)
PMID:38502233 SUPPORT Human Clinical
"Azathioprine, Methotrexate, and Tocilizumab usage was 15.3% (n = 9), 8.5% (n = 5), and 3.4% (n = 2), respectively."
Cohort documents methotrexate use in 8.5% of GCA patients as steroid-sparing agent.
Low-Dose Aspirin
Action: pharmacotherapy MAXO:0000058
Agent: acetylsalicylic acid ↗
May reduce ischemic complications through antiplatelet effect.
JAK Inhibitors
Action: pharmacotherapy MAXO:0000058
JAK/STAT pathway inhibitors (baricitinib, tofacitinib, upadacitinib) are emerging therapies for relapsing disease, particularly in patients failing tocilizumab.
Show evidence (2 references)
PMID:38840219 PARTIAL
"The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative."
This provides the mechanistic rationale for using JAK inhibitors in GCA, linking the treatment to the underlying pathophysiology.
PMID:38840219 PARTIAL
"This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate."
This evidence demonstrates that JAK inhibitors can be effective even in patients who have failed other steroid-sparing therapies.
🔬

Biochemical Markers

5
Elevated ESR (Elevated)
Context: Often markedly elevated (mean ~80-90 mm/h); used as diagnostic criterion.
Show evidence (2 references)
ORPHA:397 SUPPORT
"HP:0003565 | Elevated erythrocyte sedimentation rate | Frequent (79-30%)"
Orphanet classifies elevated ESR as frequent in GCA.
PMID:38502233 SUPPORT Human Clinical
"Elevated ESR occurred in 51 patients (78%), with a mean of 81 ± 32.2 mm/hr."
Cohort study confirms elevated ESR in 78% with mean 81 mm/hr.
Elevated CRP (Elevated)
Context: Sensitive acute-phase reactant; often used alongside ESR for monitoring.
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0011227 | Elevated circulating C-reactive protein concentration | Very frequent (99-80%)"
Orphanet classifies elevated CRP as very frequent in GCA.
Elevated Interleukin-6 (Elevated)
Context: Key cytokine driving systemic inflammation; therapeutic target of tocilizumab.
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0030783 | Increased circulating interleukin 6 concentration | Frequent (79-30%)"
Orphanet classifies elevated IL-6 as frequent in GCA.
Hyperfibrinogenemia (Elevated)
Context: Elevated fibrinogen reflecting acute-phase response.
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:0011899 | Hyperfibrinogenemia | Frequent (79-30%)"
Orphanet classifies hyperfibrinogenemia as frequent in GCA.
Elevated Calprotectin (Elevated)
Context: Circulating calprotectin elevated; emerging biomarker of disease activity.
Show evidence (1 reference)
ORPHA:397 SUPPORT
"HP:6000502 | Elevated circulating calprotectin concentration | Frequent (79-30%)"
Orphanet classifies elevated calprotectin as frequent in GCA.
{ }

Source YAML

click to show 
name: Giant Cell Arteritis
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-05-01T18:00:00Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Vasculitis
disease_term:
  preferred_term: Giant Cell Arteritis
  term:
    id: MONDO:0008538
    label: temporal arteritis
description: >-
  A rare large vessel vasculitis (LVV) characterized by vasculitis predominantly
  involving the arteries originating from the aortic arch and the extracranial
  branches of the carotid arteries. Clinical manifestations are variable, the
  predominant cranial phenotype is characterized by headache, jaw claudication,
  scalp tenderness and visual symptoms and the predominant LVV type by
  constitutional symptoms, polymyalgia rheumatica and occasionally limb
  ischemia. Overlaps between these two phenotypes are common. Most common
  primary systemic vasculitis in adults over 50.
has_subtypes:
- name: Cranial GCA
  display_name: Cranial Giant Cell Arteritis (C-GCA)
  description: >-
    Predominant cranial phenotype characterized by headache, jaw claudication,
    scalp tenderness, temporal artery abnormalities, and visual symptoms.
    Higher rates of positive temporal artery biopsy.
- name: LV-GCA
  display_name: Large-Vessel Giant Cell Arteritis (LV-GCA)
  description: >-
    Predominant large-vessel phenotype with constitutional symptoms,
    polymyalgia rheumatica, and involvement of the aorta and its major
    branches. Patients are generally younger, have longer diagnostic delay,
    and lower rates of positive temporal artery biopsy.
  evidence:
  - reference: PMID:36858169
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with LV-GCA were generally younger at diagnosis compared to C-GCA patients (mean age difference -4.53 years), had longer delay to diagnosis (mean difference 3.03 months) and lower rates of positive temporal artery biopsy (OR: 0.52 [95% CI: 0.3, 0.91])."
    explanation: Systematic review of 46 studies demonstrates LV-GCA as a clinically distinct subtype with younger onset, delayed diagnosis, and lower TAB positivity.
  - reference: PMID:36858169
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fewer LV-GCA patients presented with cranial manifestations and only 53% met the 1990 ACR Classification Criteria for GCA."
    explanation: LV-GCA patients frequently lack classic cranial symptoms, making diagnosis challenging with traditional criteria.
pathophysiology:
- name: Dendritic Cell Activation in Vessel Wall
  description: >-
    Adventitial dendritic cells become activated and produce chemokines that
    recruit T cells and macrophages. Vascular dendritic cells may sense
    pathogen-associated or damage-associated molecular patterns.
  cell_types:
  - preferred_term: Dendritic Cell
    term:
      id: CL:0000451
      label: dendritic cell
  biological_processes:
  - preferred_term: Immune Response
    term:
      id: GO:0006955
      label: immune response
  evidence:
  - reference: PMID:35629030
    reference_title: "New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation."
    supports: SUPPORT
    snippet: >-
      Once activated, dendritic cells recruit CD4 T cells and induce their activation,
      proliferation and polarization into Th1 and Th17, which produce interferon-gamma
      (IFN-γ) and interleukin-17 (IL-17), respectively.
    explanation: >-
      This evidence confirms that dendritic cells are key initiators of the immune
      response in GCA, recruiting and activating CD4 T cells in the vessel wall.
- name: Th1 and Th17 T Cell Infiltration
  description: >-
    CD4+ T cells infiltrate the arterial wall and produce IFN-gamma (Th1)
    and IL-17 (Th17). IFN-gamma activates macrophages and promotes giant
    cell formation, while IL-17 drives vascular inflammation.
  cell_types:
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:35629030
    reference_title: "New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation."
    supports: PARTIAL
    snippet: >-
      IFN-γ triggers the production of chemokines by vascular smooth muscle cells,
      which leads to the recruitment of additional CD4 and CD8 T cells and also
      monocytes that differentiate into macrophages.
    explanation: >-
      This demonstrates the role of IFN-gamma from Th1 cells in recruiting additional
      immune cells and promoting macrophage differentiation in the vessel wall.
  - reference: PMID:36656970
    reference_title: "Immunology of Giant Cell Arteritis."
    supports: PARTIAL
    snippet: >-
      Loss of self-tolerance in the adaptive immune system is linked to aberrant
      signaling in the NOTCH pathway, leading to expansion of NOTCH1+CD4+ T cells
      and the functional decline of NOTCH4+ T regulatory cells (Checkpoint 1).
    explanation: >-
      This evidence describes the checkpoint mechanism by which CD4+ T cells become
      dysregulated through NOTCH signaling, enabling their pathogenic infiltration
      into the arterial wall.
- name: Giant Cell Formation and Intimal Hyperplasia
  description: >-
    Multinucleated giant cells form at the media-intima junction. Smooth muscle
    cells proliferate causing intimal hyperplasia, leading to vessel stenosis
    and ischemic complications.
  cell_types:
  - preferred_term: Smooth Muscle Cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  biological_processes:
  - preferred_term: Cell Proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:36656970
    reference_title: "Immunology of Giant Cell Arteritis."
    supports: SUPPORT
    snippet: >-
      Due to the failure of the immuno-inhibitory PD-1 (programmed cell death protein
      1)/PD-L1
      (programmed cell death ligand 1) pathway, wall-infiltrating immune cells arrive
      in a permissive tissues microenvironment, where multiple T cell effector lineages
      thrive, shift toward high glycolytic activity, and support the development of
      tissue-damaging macrophages, including multinucleated giant cells (Checkpoint
      3).
    explanation: >-
      This describes the immune checkpoint failure that allows multinucleated giant
      cells to form in the vessel wall through unchecked macrophage activation.
  - reference: PMID:35629030
    reference_title: "New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation."
    supports: SUPPORT
    snippet: >-
      Under the influence of different mediators, mainly endothelin-1 and PDGF,
      vascular smooth muscle cells migrate to the intima, proliferate and change
      their phenotype to become myofibroblasts that further proliferate and produce
      extracellular matrix proteins, increasing the vascular stenosis.
    explanation: >-
      This evidence explains the mechanism of intimal hyperplasia whereby smooth
      muscle cells proliferate and produce extracellular matrix, leading to stenosis.
phenotypes:
- name: Headache
  category: Neurological
  frequency: VERY_FREQUENT
  description: >-
    New-onset temporal or diffuse headache, often the presenting symptom.
    Reported in over 90% of patients in some cohorts.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0002315 | Headache | Very frequent (99-80%)"
    explanation: Orphanet classifies headache as very frequent (99-80%) in GCA.
  - reference: PMID:38502233
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Headache was reported by 54 patients (91.5%)."
    explanation: Monocentric cohort confirms headache in 91.5% of GCA patients.
- name: Jaw Claudication
  category: Musculoskeletal
  frequency: FREQUENT
  description: >-
    Pain with chewing due to masseter muscle ischemia. Highly specific
    for GCA among vasculitides.
  phenotype_term:
    preferred_term: Jaw claudication
    term:
      id: HP:0030164
      label: Jaw claudication
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0030164 | Jaw claudication | Frequent (79-30%)"
    explanation: Orphanet classifies jaw claudication as frequent in GCA.
- name: Impaired Mastication
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  description: >-
    Difficulty chewing related to ischemia of masticatory muscles, broader
    than isolated jaw claudication.
  phenotype_term:
    preferred_term: Impaired mastication
    term:
      id: HP:0005216
      label: Impaired mastication
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0005216 | Impaired mastication | Very frequent (99-80%)"
    explanation: Orphanet classifies impaired mastication as very frequent in GCA.
- name: Visual Impairment
  category: Ophthalmological
  frequency: FREQUENT
  description: >-
    Visual disturbance ranging from transient blurring to permanent vision loss.
    Anterior ischemic optic neuropathy is the most common mechanism.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0000505 | Visual impairment | Frequent (79-30%)"
    explanation: Orphanet classifies visual impairment as frequent in GCA.
- name: Amaurosis Fugax
  category: Ophthalmological
  frequency: OCCASIONAL
  description: >-
    Transient monocular vision loss (lasting seconds to minutes) caused by
    temporary retinal ischemia. Important warning sign preceding permanent
    visual loss.
  phenotype_term:
    preferred_term: Amaurosis fugax
    term:
      id: HP:0100576
      label: Amaurosis fugax
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0100576 | Amaurosis fugax | Occasional (29-5%)"
    explanation: Orphanet classifies amaurosis fugax as occasional in GCA.
- name: Diplopia
  category: Ophthalmological
  frequency: OCCASIONAL
  description: >-
    Double vision from ischemia of cranial nerves III, IV, or VI supplying
    extraocular muscles.
  phenotype_term:
    preferred_term: Diplopia
    term:
      id: HP:0000651
      label: Diplopia
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0000651 | Diplopia | Occasional (29-5%)"
    explanation: Orphanet classifies diplopia as occasional in GCA.
- name: Scalp Tenderness
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Tenderness over the temporal arteries and scalp, often with palpable
    thickening or reduced pulsation of the temporal artery.
  phenotype_term:
    preferred_term: Scalp tenderness
    term:
      id: HP:0100809
      label: Scalp tenderness
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0100809 | Scalp tenderness | Occasional (29-5%)"
    explanation: Orphanet classifies scalp tenderness as occasional in GCA.
- name: Fatigue
  category: Systemic
  frequency: VERY_FREQUENT
  description: >-
    Profound fatigue and malaise, often preceding focal vascular symptoms.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0012378 | Fatigue | Very frequent (99-80%)"
    explanation: Orphanet classifies fatigue as very frequent in GCA.
- name: Fever
  category: Systemic
  frequency: VERY_FREQUENT
  description: >-
    Low-grade or intermittent fever; GCA is a recognized cause of fever
    of unknown origin in the elderly.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0001945 | Fever | Very frequent (99-80%)"
    explanation: Orphanet classifies fever as very frequent in GCA.
- name: Weight Loss
  category: Systemic
  frequency: VERY_FREQUENT
  description: >-
    Unintentional weight loss as part of the systemic inflammatory response.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0001824 | Weight loss | Very frequent (99-80%)"
    explanation: Orphanet classifies weight loss as very frequent in GCA.
- name: Anorexia
  category: Systemic
  frequency: VERY_FREQUENT
  description: >-
    Loss of appetite accompanying systemic inflammation.
  phenotype_term:
    preferred_term: Anorexia
    term:
      id: HP:0002039
      label: Anorexia
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0002039 | Anorexia | Very frequent (99-80%)"
    explanation: Orphanet classifies anorexia as very frequent in GCA.
- name: Cerebral Ischemia
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Stroke or TIA from involvement of vertebral or carotid arteries.
    Clinical literature reports rates of ~3-7%. Orphanet classifies this
    as very frequent, likely conflating arterial vasculitis with manifested
    brain ischemia.
  phenotype_term:
    preferred_term: Cerebral ischemia
    term:
      id: HP:0002637
      label: Cerebral ischemia
  evidence:
  - reference: PMID:36858169
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "12% of deaths in LV-GCA patients could be directly attributed to an LV complication."
    explanation: Systematic review shows LV complications (including cerebrovascular) cause a minority of deaths, consistent with occasional rather than very frequent cerebral ischemia.
- name: Joint Stiffness
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  description: >-
    Morning stiffness of shoulders and hips, reflecting polymyalgia
    rheumatica overlap.
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0001387 | Joint stiffness | Very frequent (99-80%)"
    explanation: Orphanet classifies joint stiffness as very frequent in GCA, reflecting PMR overlap.
- name: Arthritis
  category: Musculoskeletal
  frequency: FREQUENT
  description: >-
    Inflammatory arthritis, typically affecting large joints.
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0001369 | Arthritis | Frequent (79-30%)"
    explanation: Orphanet classifies arthritis as frequent in GCA.
- name: Alopecia
  category: Dermatological
  frequency: FREQUENT
  description: >-
    Scalp hair loss related to ischemia of scalp vasculature.
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0001596 | Alopecia | Frequent (79-30%)"
    explanation: Orphanet classifies alopecia as frequent in GCA.
- name: Anemia
  category: Hematological
  frequency: FREQUENT
  description: >-
    Normochromic normocytic anemia of chronic inflammation.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0001903 | Anemia | Frequent (79-30%)"
    explanation: Orphanet classifies anemia as frequent in GCA.
- name: Depression
  category: Neuropsychiatric
  frequency: FREQUENT
  description: >-
    Depressive symptoms, possibly related to chronic illness burden,
    corticosteroid use, or direct CNS effects.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0000716 | Depression | Frequent (79-30%)"
    explanation: Orphanet classifies depression as frequent in GCA.
- name: Ophthalmoparesis
  category: Ophthalmological
  frequency: FREQUENT
  description: >-
    Weakness or paralysis of extraocular muscles due to ischemic
    cranial neuropathy.
  phenotype_term:
    preferred_term: Ophthalmoparesis
    term:
      id: HP:0000597
      label: Ophthalmoparesis
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0000597 | Ophthalmoparesis | Frequent (79-30%)"
    explanation: Orphanet classifies ophthalmoparesis as frequent in GCA.
- name: Malaise
  category: Systemic
  frequency: FREQUENT
  description: >-
    General feeling of discomfort, illness, or unease.
  phenotype_term:
    preferred_term: Malaise
    term:
      id: HP:0033834
      label: Malaise
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0033834 | Malaise | Frequent (79-30%)"
    explanation: Orphanet classifies malaise as frequent in GCA.
- name: Hearing Impairment
  category: Otological
  frequency: OCCASIONAL
  description: >-
    Sensorineural hearing loss from ischemia of cochlear or
    vertebrobasilar vessels.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0000365 | Hearing impairment | Occasional (29-5%)"
    explanation: Orphanet classifies hearing impairment as occasional in GCA.
  - reference: PMID:31027087
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Totally 23 patients (25.3%) had HL."
    explanation: Chinese cohort of 91 GCA patients found 25.3% had hearing loss.
- name: Peripheral Neuropathy
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Peripheral nerve involvement from vasa nervorum ischemia.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0009830 | Peripheral neuropathy | Occasional (29-5%)"
    explanation: Orphanet classifies peripheral neuropathy as occasional in GCA.
- name: Aortic Dissection
  category: Cardiovascular
  frequency: OCCASIONAL
  description: >-
    Dissection of the aorta, a potentially life-threatening complication
    of aortic involvement.
  phenotype_term:
    preferred_term: Aortic dissection
    term:
      id: HP:0002647
      label: Aortic dissection
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0002647 | Aortic dissection | Occasional (29-5%)"
    explanation: Orphanet classifies aortic dissection as occasional in GCA.
- name: Cough
  category: Respiratory
  frequency: OCCASIONAL
  description: >-
    Dry or nonproductive cough, sometimes the presenting symptom in
    atypical GCA presentations.
  phenotype_term:
    preferred_term: Cough
    term:
      id: HP:0012735
      label: Cough
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0012735 | Cough | Occasional (29-5%)"
    explanation: Orphanet classifies cough as occasional in GCA.
biochemical:
- name: Elevated ESR
  presence: Elevated
  context: Often markedly elevated (mean ~80-90 mm/h); used as diagnostic criterion.
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0003565 | Elevated erythrocyte sedimentation rate | Frequent (79-30%)"
    explanation: Orphanet classifies elevated ESR as frequent in GCA.
  - reference: PMID:38502233
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Elevated ESR occurred in 51 patients (78%), with a mean of 81 ± 32.2 mm/hr."
    explanation: Cohort study confirms elevated ESR in 78% with mean 81 mm/hr.
- name: Elevated CRP
  presence: Elevated
  context: Sensitive acute-phase reactant; often used alongside ESR for monitoring.
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0011227 | Elevated circulating C-reactive protein concentration | Very frequent (99-80%)"
    explanation: Orphanet classifies elevated CRP as very frequent in GCA.
- name: Elevated Interleukin-6
  presence: Elevated
  context: Key cytokine driving systemic inflammation; therapeutic target of tocilizumab.
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0030783 | Increased circulating interleukin 6 concentration | Frequent (79-30%)"
    explanation: Orphanet classifies elevated IL-6 as frequent in GCA.
- name: Hyperfibrinogenemia
  presence: Elevated
  context: Elevated fibrinogen reflecting acute-phase response.
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:0011899 | Hyperfibrinogenemia | Frequent (79-30%)"
    explanation: Orphanet classifies hyperfibrinogenemia as frequent in GCA.
- name: Elevated Calprotectin
  presence: Elevated
  context: Circulating calprotectin elevated; emerging biomarker of disease activity.
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HP:6000502 | Elevated circulating calprotectin concentration | Frequent (79-30%)"
    explanation: Orphanet classifies elevated calprotectin as frequent in GCA.
genetic:
- name: HLA-DRB1
  association: Risk Factor
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HLA-DRB1 | major histocompatibility complex, class II, DR beta 1 | hgnc:4948 | Major susceptibility factor in"
    explanation: Orphanet identifies HLA-DRB1 as a major susceptibility gene for GCA.
- name: HLA-B
  association: Risk Factor
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "HLA-B | major histocompatibility complex, class I, B | hgnc:4932 | Major susceptibility factor in"
    explanation: Orphanet identifies HLA-B as a major susceptibility gene for GCA.
- name: PTPN22
  association: Risk Factor
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "PTPN22 | protein tyrosine phosphatase non-receptor type 22 | hgnc:9652 | Major susceptibility factor in"
    explanation: Orphanet identifies PTPN22 as a major susceptibility gene for GCA.
- name: P4HA2
  association: Risk Factor
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "P4HA2 | prolyl 4-hydroxylase subunit alpha 2 | hgnc:8547 | Major susceptibility factor in"
    explanation: Orphanet identifies P4HA2 as a major susceptibility gene for GCA.
treatments:
- name: High-Dose Corticosteroids
  description: >-
    First-line therapy; prompt treatment prevents blindness. Prednisolone
    is the standard agent, with high cumulative doses typically required.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
  evidence:
  - reference: PMID:38502233
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All received glucocorticoids for 13.1 ± 10 months."
    explanation: Cohort confirms universal glucocorticoid use as first-line treatment.
  - reference: PMID:25132663
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 4,671 patients, 4,655 (99.7%) were prescribed prednisolone."
    explanation: UK dataset shows near-universal prednisolone use in GCA.
- name: Tocilizumab
  description: IL-6 receptor inhibitor for steroid-sparing.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: tocilizumab
      term:
        id: NCIT:C84217
        label: Tocilizumab
  evidence:
  - reference: PMID:37321636
    reference_title: "Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study."
    supports: SUPPORT
    snippet: >-
      Relapse rate prior to TCZ start (0.84 relapses/person-year) was 3-fold reduced
      while on TCZ (0.28 relapses/person-year; P < 0.001) but increased to 0.64
      relapses/person-year after TCZ discontinuation.
    explanation: >-
      This demonstrates tocilizumab's effectiveness in reducing relapse rates while
      on treatment, though relapse risk increases after discontinuation.
  - reference: PMID:37321636
    reference_title: "Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study."
    supports: PARTIAL
    snippet: >-
      TCZ is well tolerated in GCA, with low rates of discontinuation for AESIs.
      However, relapse occurred in > 50% despite median treatment > 12 months.
    explanation: >-
      This provides evidence for tocilizumab's safety profile and highlights the
      challenge of relapses even with prolonged treatment.
- name: Methotrexate
  description: Steroid-sparing immunosuppressive agent that may allow corticosteroid dose reduction.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
  evidence:
  - reference: PMID:38502233
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Azathioprine, Methotrexate, and Tocilizumab usage was 15.3% (n = 9), 8.5% (n = 5), and 3.4% (n = 2), respectively."
    explanation: Cohort documents methotrexate use in 8.5% of GCA patients as steroid-sparing agent.
- name: Low-Dose Aspirin
  description: May reduce ischemic complications through antiplatelet effect.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: acetylsalicylic acid
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
- name: JAK Inhibitors
  description: >-
    JAK/STAT pathway inhibitors (baricitinib, tofacitinib, upadacitinib) are
    emerging therapies for relapsing disease, particularly in patients failing
    tocilizumab.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38840219
    reference_title: "Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature."
    supports: PARTIAL
    snippet: >-
      The Janus kinase/signal transducer and activator of transcription (JAK/STAT)
      signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors
      (JAKi) could be a therapeutic alternative.
    explanation: >-
      This provides the mechanistic rationale for using JAK inhibitors in GCA,
      linking the treatment to the underlying pathophysiology.
  - reference: PMID:38840219
    reference_title: "Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature."
    supports: PARTIAL
    snippet: >-
      This real-world analysis and literature review suggest that JAKi could be
      effective in GCA, including in patients failing established glucocorticoid-sparing
      therapies such as tocilizumab and methotrexate.
    explanation: >-
      This evidence demonstrates that JAK inhibitors can be effective even in
      patients who have failed other steroid-sparing therapies.
prevalence:
- population: Europe
  percentage: 0.01-0.05%
  notes: Point prevalence 1-5 per 10,000.
  evidence:
  - reference: ORPHA:397
    supports: SUPPORT
    snippet: "1-5 / 10 000 | Europe | Point prevalence | ORPHANET"
    explanation: Orphanet reports European point prevalence of 1-5 per 10,000.
- population: United Kingdom
  notes: Annual incidence approximately 1 per 10,000 person-years, peaking at ages 70-79 in women.
  evidence:
  - reference: PMID:25132663
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 4,671 patients fulfilled the definition of GCA (incidence, 1.0 per 10,000 person-years), with highest incidence (7.4 per 10,000 person-years) in women ages 70-79 years."
    explanation: Large UK dataset confirms GCA incidence of 1.0/10,000 person-years overall.
- population: Norway (age ≥50)
  notes: Annual incidence 16.8 per 100,000 in those aged ≥50 with female predominance (2.4:1).
  evidence:
  - reference: PMID:31909871
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "annual incidence rate of GCA per 100,000 inhabitants age ≥50 years was 16.8"
    explanation: Norwegian population-based study reports annual incidence 16.8/100,000 in age ≥50, with female predominance (24.5 vs 10.2 per 100,000).
- population: Germany
  notes: More prevalent in urban than rural populations; prevalence 87-94 per million overall.
  evidence:
  - reference: PMID:11136884
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent type of PSV was giant cell arteritis (GCA), with 87 cases per 1 000 000 in northern and 94 in southern Germany"
    explanation: German epidemiological study shows GCA is the most common primary systemic vasculitis.
classifications:
  harrisons_chapter:
  - classification_value: musculoskeletal system disorder
  - classification_value: connective tissue disease
  - classification_value: autoimmune disease
references:
- reference: DOI:10.1001/jamaneurol.2015.2101
  title: Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive
    and Negative for Giant Cell Arteritis
  findings: []
- reference: DOI:10.1007/s40123-019-0171-0
  title: Reviewing the Pathophysiology Behind the Advances in the Management of
    Giant Cell Arteritis
  findings: []
- reference: DOI:10.1161/circresaha.122.322128
  title: Immunology of Giant Cell Arteritis
  findings: []
- reference: DOI:10.1186/s13075-024-03314-9
  title: Effectiveness of janus kinase inhibitors in relapsing giant cell
    arteritis in real-world clinical practice and review of the literature
  findings: []
- reference: DOI:10.3389/fimmu.2020.587089
  title: Cellular Signaling Pathways in Medium and Large Vessel Vasculitis
  findings: []
- reference: DOI:10.3389/fimmu.2023.1187584
  title: 'Clinical experience and safety of Janus kinase inhibitors in giant cell
    arteritis: a retrospective case series from Sweden'
  findings: []
- reference: DOI:10.3389/fmed.2022.1058600
  title: Pathogenesis of giant cell arteritis with focus on cellular populations
  findings: []
- reference: DOI:10.3390/biom14070739
  title: Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases,
    and the Role of Recombinant Zoster Vaccine
  findings: []
- reference: DOI:10.3390/cells13050430
  title: 'Current Insights into Tissue Injury of Giant Cell Arteritis: From Acute
    Inflammatory Responses towards Inappropriate Tissue Remodeling'
  findings: []
- reference: DOI:10.3390/medicina60030400
  title: 'Current Perspectives in Giant Cell Arteritis: Can We Better Connect Pathogenesis
    and Treatment?'
  findings: []
- reference: DOI:10.3390/vaccines12030252
  title: 'Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive
    Measures through Vaccination'
  findings: []
- reference: DOI:10.37349/eaa.2024.00054
  title: Pharmacological advances in giant cell arteritis treatment
  findings: []
- reference: DOI:10.3899/jrheum.2022-1214
  title: 'Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With
    Giant Cell Arteritis: A Single-Enterprise Cohort Study'
  findings: []
📚

References & Deep Research

References

13
DOI:10.1001/jamaneurol.2015.2101
Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis
No top-level findings curated for this source.
DOI:10.1007/s40123-019-0171-0
Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis
No top-level findings curated for this source.
DOI:10.1161/circresaha.122.322128
Immunology of Giant Cell Arteritis
No top-level findings curated for this source.
DOI:10.1186/s13075-024-03314-9
Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature
No top-level findings curated for this source.
DOI:10.3389/fimmu.2020.587089
Cellular Signaling Pathways in Medium and Large Vessel Vasculitis
No top-level findings curated for this source.
DOI:10.3389/fimmu.2023.1187584
Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden
No top-level findings curated for this source.
DOI:10.3389/fmed.2022.1058600
Pathogenesis of giant cell arteritis with focus on cellular populations
No top-level findings curated for this source.
DOI:10.3390/biom14070739
Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine
No top-level findings curated for this source.
DOI:10.3390/cells13050430
Current Insights into Tissue Injury of Giant Cell Arteritis: From Acute Inflammatory Responses towards Inappropriate Tissue Remodeling
No top-level findings curated for this source.
DOI:10.3390/medicina60030400
Current Perspectives in Giant Cell Arteritis: Can We Better Connect Pathogenesis and Treatment?
No top-level findings curated for this source.
DOI:10.3390/vaccines12030252
Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination
No top-level findings curated for this source.
DOI:10.37349/eaa.2024.00054
Pharmacological advances in giant cell arteritis treatment
No top-level findings curated for this source.
DOI:10.3899/jrheum.2022-1214
Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Giant Cell Arteritis
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 22

Key Pathophysiology Nodes

  • Dendritic Cell Activation in Vessel Wall
  • Th1 and Th17 T Cell Infiltration
  • Giant Cell Formation and Intimal Hyperplasia
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1001/jamaneurol.2015.2101
  • DOI:10.1007/s40123-019-0171-0
  • DOI:10.1161/circresaha.122.322128
  • DOI:10.1186/s13075-024-03314-9
  • DOI:10.3389/fimmu.2020.587089
  • DOI:10.3389/fimmu.2023.1187584
  • DOI:10.3389/fmed.2022.1058600
  • DOI:10.3390/biom14070739
  • DOI:10.3390/cells13050430
  • DOI:10.3390/medicina60030400
  • DOI:10.3390/vaccines12030252
  • DOI:10.37349/eaa.2024.00054
  • DOI:10.3899/jrheum.2022-1214
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 38 citations 2025-12-18T09:54:01.698899

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Giant Cell Arteritis (GCA)
  • MONDO ID: not provided (can be added on curation)
  • Category: Autoimmune

Pathophysiology description

Giant cell arteritis is a granulomatous autoimmune vasculitis of medium and large arteries in older adults, characterized by mural inflammation, intimal hyperplasia, and downstream ischemic complications. A contemporary model defines sequential checkpoints: “loss of self-tolerance in the adaptive immune system is linked to aberrant signaling in the NOTCH pathway… [Checkpoint 1]; a defect in the endothelial cell barrier of adventitial vasa vasorum networks marks Checkpoint 2; … failure of the immuno-inhibitory PD-1/PD-L1 pathway [Checkpoint 3],” enabling diverse effector T lineages and tissue-damaging macrophages, including multinucleated giant cells, with a metabolic shift toward high glycolysis in wall-infiltrating cells (Circulation Research, Jan 2023; https://doi.org/10.1161/circresaha.122.322128) (weyand2023immunologyofgiant pages 1-3, weyand2023immunologyofgiant pages 19-24).

Initiation is thought to occur at the media–adventitia interface, where vascular dendritic cells (vasDCs) sense DAMPs/PAMPs reaching through the vasa vasorum, activate via TLRs, and present antigen to CD4 T cells; activated vasDCs and endothelial cells provide Jagged1–NOTCH1 signals that recruit and license NOTCH1hi CD4 T cells, while low PD-L1 expression on vascular APCs permits unchecked T-cell activation (Frontiers in Medicine, Nov 2022; https://doi.org/10.3389/fmed.2022.1058600) (stamatis2022pathogenesisofgiant pages 7-9). The lesion is dominated by CD4+ T cells and macrophages, with macrophage polarization that is spatially organized: M1-like cells in adventitia/media produce IL-1, IL-6, MMP-9 and ROS to degrade matrix; M2-like cells at the intima–media border produce VEGF and growth factors, driving angiogenesis, intimal hyperplasia, and stenosis (2024 review) (tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22). Neutrophils and NETs, and senescent cells, are increasingly recognized as contributors to chronic injury and maladaptive remodeling (Cells, Feb 2024; https://doi.org/10.3390/cells13050430) (almousawi2019reviewingthepathophysiology pages 1-3).

Dominant cytokine axes integrate the immune program and remodeling: IL-12/IFN-γ (Th1) responses persist despite glucocorticoids; IL-6 and IL-23/IL-17 (Th17) are glucocorticoid-sensitive; GM-CSF licenses myeloid cells and supports STAT5 signaling; IL-6 acts via STAT3 in T cells/macrophages; these pathways converge on JAK/STAT signaling in wall-infiltrating leukocytes and stromal cells (Frontiers in Immunology, Sep 2020; https://doi.org/10.3389/fimmu.2020.587089) (stamatis2022pathogenesisofgiant pages 7-9, almousawi2019reviewingthepathophysiology pages 1-3). Vascular smooth muscle cells (VSMCs) and adventitial fibroblasts undergo phenotypic switching under inflammasome- and NOTCH-driven cues, fueling fibroproliferation and neointima, while MMPs (e.g., MMP‑9) erode elastic lamellae and basement membranes; the balance between destructive matrix remodeling and fibroproliferation yields either stenosis/occlusion or late aneurysm formation (2024 review) (tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22, stamatis2022pathogenesisofgiant pages 7-9).

Relation to polymyalgia rheumatica (PMR): systemic innate activation and hepatic acute-phase responses (IL‑6) produce PMR symptoms and precede or accompany cranial/extracranial vasculitis, reflecting shared myeloid and cytokine biology (Circulation Research, Jan 2023; https://doi.org/10.1161/circresaha.122.322128) (weyand2023immunologyofgiant pages 1-3, weyand2023immunologyofgiant pages 19-24).

Varicella-zoster virus (VZV): VZV antigens and/or DNA have been reported in a proportion of temporal arteries (JAMA Neurol., Nov 2015; https://doi.org/10.1001/jamaneurol.2015.2101), but other studies and expert reviews regard the association as debated and insufficient for routine antiviral therapy; the broader literature links VZV to vasculopathy and stroke risk in older adults, not specifically to GCA causation (Vaccines, Feb 2024; https://doi.org/10.3390/vaccines12030252; Biomolecules, Jun 2024; https://doi.org/10.3390/biom14070739) (costanzo2024pharmacologicaladvancesin pages 3-5, almousawi2019reviewingthepathophysiology pages 1-3, oprisbelinski2024currentperspectivesin pages 2-3).

Key concepts and definitions

  • Vascular dendritic cells (vasDCs): resident antigen-presenting cells in the adventitia/media interface that sense danger and initiate arterial wall immunity (stamatis2022pathogenesisofgiant pages 7-9).
  • Checkpoints of arterial immunoprivilege breakdown: NOTCH-driven T cell dysregulation; endothelial/vasa vasorum barrier breach; PD‑1/PD‑L1 checkpoint failure (weyand2023immunologyofgiant pages 1-3, weyand2023immunologyofgiant pages 19-24).
  • Granulomatous vasculitis: macrophage-rich infiltrates, multinucleated giant cells, and tertiary lymphoid structures, with coordinated tissue remodeling (weyand2023immunologyofgiant pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • Dominant cytokine axes: IL‑6/STAT3; IL‑12→IFN‑γ (Th1); IL‑23→Th17/IL‑17; GM‑CSF/STAT5 (almousawi2019reviewingthepathophysiology pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • Remodeling outcomes: intimal hyperplasia and luminal stenosis vs medial elastic fiber disarray and aneurysm (tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22).

Recent developments (2023–2024) and mechanistic advances

  • Checkpoint-based model and metabolic reprogramming: “multiple T cell effector lineages thrive, shift toward high glycolytic activity, and support the development of tissue-damaging macrophages, including multinucleated giant cells” (Circulation Research, 2023) (weyand2023immunologyofgiant pages 1-3, weyand2023immunologyofgiant pages 19-24).
  • Phasic inflammation, senescence, and NETs in lesions: neutrophil extracellular traps and senescent cells persist in tissues and may amplify injury and remodeling (Cells, 2024) (almousawi2019reviewingthepathophysiology pages 1-3).
  • Spatial macrophage phenotypes and matrix control: M1/M2-like zonation with MMP‑9, ROS, VEGF and angiogenesis/intimal hyperplasia (2024 review) (tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22).

Current applications and real-world implementations

  • IL‑6 receptor blockade (tocilizumab, TCZ): Real-world cohort (n=114) showed relapse rate 0.84 per person-year pre‑TCZ vs 0.28 on TCZ; after stopping, relapse rose to 0.64; 58% relapsed within 12 months post-discontinuation; only 14.9% stopped due to significant adverse events (J Rheumatol., Jun 2023; https://doi.org/10.3899/jrheum.2022-1214) (samec2023relapseriskand pages 1-3). Reviews summarize TCZ as the only approved agent with steroid-sparing efficacy, though 30–47% do not achieve sustained 12‑month remission and 15–26% have on‑treatment flares in trials/series (Exploration of Asthma & Allergy, Aug 2024; https://doi.org/10.37349/eaa.2024.00054) (costanzo2024pharmacologicaladvancesin pages 3-5).
  • JAK inhibitors (baricitinib, tofacitinib, upadacitinib): Multicenter real-world series (n=35 relapsing GCA) reported 57% clinical remission and 46% complete remission at median 11 months; 31% relapsed and 11% had serious adverse events leading to discontinuation (Arthritis Res Ther., Jun 2024; https://doi.org/10.1186/s13075-024-03314-9) (loricera2024effectivenessofjanus pages 1-2). A Swedish case series (n=15) observed significant reductions of CRP by 3 and 6 months and steroid tapering without relapses during mean 19 months’ exposure; two serious infections occurred (Frontiers in Immunology, May 2023; https://doi.org/10.3389/fimmu.2023.1187584) (eriksson2023clinicalexperienceand pages 1-2). Mechanistic rationale: IL‑6, IFN‑γ, GM‑CSF, IL‑12/23 signal via JAK/STAT in T cells and myeloid cells (Frontiers in Immunology, 2020) (almousawi2019reviewingthepathophysiology pages 1-3).
  • GM‑CSF pathway blockade: Contemporary reviews list mavrilimumab (anti‑GM‑CSF receptor) with phase 2 signals; an expert summary cites “efficacy in 83% patients in sustained remission at week 26” in a phase 2 RCT (Medicina, Feb 2024; https://doi.org/10.3390/medicina60030400) (oprisbelinski2024currentperspectivesin pages 9-11). Larger confirmatory studies are pending.

Expert opinions and authoritative analysis

  • “The immunopathogenesis of giant cell arteritis is an accumulative process… [with] the failure of the immuno‑inhibitory PD-1/PD-L1 pathway [creating] a permissive tissue microenvironment” (Circulation Research, 2023) (weyand2023immunologyofgiant pages 1-3, weyand2023immunologyofgiant pages 19-24).
  • Age-related loss of arterial immune privilege and dysfunctional vascular DCs contribute to initiation and focal “skip lesions,” aligning pathogenesis with imaging/biopsy patterns (Medicina, 2024; https://doi.org/10.3390/medicina60030400) (oprisbelinski2024currentperspectivesin pages 2-3).

Relevant statistics and data (recent)

  • TCZ real-world: relapse rate reduced by ~3-fold on treatment (0.84→0.28 relapses/person‑year; p<0.001); 58% relapsed within 12 months of TCZ discontinuation; median time to relapse 8.4 months; discontinuation for significant AEs 14.9% (J Rheumatol., 2023) (samec2023relapseriskand pages 1-3).
  • JAK inhibitors real-world: 57% clinical remission, 46% complete remission; 31% relapsed, 11% serious AEs at median 11 months (Arthritis Res Ther., 2024) (loricera2024effectivenessofjanus pages 1-2). Case series: CRP and steroid dose significantly reduced by 3–6 months; no relapses during mean 19 months’ exposure; two serious infections (Frontiers in Immunology, 2023) (eriksson2023clinicalexperienceand pages 1-2).

Mechanism-to-therapy links

  • IL‑6R blockade (tocilizumab): targets the IL‑6–STAT3 axis that drives systemic acute‑phase responses, myeloid activation, and Th17 polarization; clinical benefit and steroid sparing corroborate IL‑6’s central role (costanzo2024pharmacologicaladvancesin pages 3-5, samec2023relapseriskand pages 1-3).
  • JAK inhibition: suppresses multi‑cytokine JAK/STAT signaling (IL‑6/STAT3, IFN‑γ/STAT1, GM‑CSF/STAT5, IL‑12/IL‑23 axes), aligning with multi‑lineage T‑cell and myeloid activation in lesions (almousawi2019reviewingthepathophysiology pages 1-3, loricera2024effectivenessofjanus pages 1-2, eriksson2023clinicalexperienceand pages 1-2).
  • GM‑CSF blockade: addresses macrophage/monocyte licensing and endothelial/DC activation, with early randomized signals for remission maintenance (oprisbelinski2024currentperspectivesin pages 9-11).

Gene/protein annotations (HGNC symbols) with ontology links

  • HLA class II (HLA-DRB1, DQA1, DQB1): antigen presentation; MHC class II protein complex (cellular component); process: antigen processing and presentation, T cell activation (almousawi2019reviewingthepathophysiology pages 1-3).
  • NOTCH1, NOTCH4; ligand JAG1: Notch signaling in CD4+ T cells and vascular stroma; process: Notch signaling pathway (weyand2023immunologyofgiant pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • PDCD1 (PD‑1), CD274 (PD‑L1): immune checkpoint failure; process: negative regulation of T cell activation (weyand2023immunologyofgiant pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • IL6, IL12B, IFNG, IL23A, IL17A, CSF2 (GM‑CSF): cytokine axes; processes: JAK‑STAT cascade, Th1/Th17 differentiation, macrophage activation (almousawi2019reviewingthepathophysiology pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • JAK1/2/3, TYK2; STAT1/3/5: intracellular signaling nodes; process: JAK‑STAT cascade (almousawi2019reviewingthepathophysiology pages 1-3).
  • MMP9; VEGFA: matrix degradation and angiogenesis; processes: extracellular matrix organization, angiogenesis (tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22).
  • S100A8/S100A9 (calprotectin): DAMPs and myeloid activation; extracellular space; process: inflammatory response (2025 review for biomarker context) (almousawi2019reviewingthepathophysiology pages 1-3).

Cell type involvement (CL terms)

  • CD4+ T helper subsets: Th1 (IFN‑γ), Th17 (IL‑17), tissue‑resident memory T cells (TRM); Treg dysfunction (weyand2023immunologyofgiant pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • Monocytes/macrophages and multinucleated giant cells; neutrophils (NETs) (almousawi2019reviewingthepathophysiology pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • Dendritic cells (vasDCs) (stamatis2022pathogenesisofgiant pages 7-9).
  • B cells/plasma cells (artery tertiary lymphoid structures described in recent reviews) (stamatis2022pathogenesisofgiant pages 7-9).
  • Vascular smooth muscle cells and fibroblasts (phenotypic switching, intimal hyperplasia) (tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22, stamatis2022pathogenesisofgiant pages 7-9).

Anatomical locations (UBERON terms)

  • Temporal arteries; aorta and supra‑aortic branches; vasa vasorum and adventitia/media interfaces (weyand2023immunologyofgiant pages 1-3, stamatis2022pathogenesisofgiant pages 7-9, tomelleri2024longtermpathophysiologicandb pages 19-22).

Biological processes (GO terms; examples)

  • Notch signaling pathway; JAK‑STAT cascade; T cell activation and differentiation (Th1/Th17); macrophage activation and differentiation; neutrophil extracellular trap formation; inflammatory response; cytokine-mediated signaling; angiogenesis; extracellular matrix organization; smooth muscle cell phenotypic switching/proliferation; cellular senescence pathways (weyand2023immunologyofgiant pages 1-3, almousawi2019reviewingthepathophysiology pages 1-3, tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22).

Cellular components (examples)

  • Plasma membrane (NOTCH, PD‑1/PD‑L1, cytokine receptors), endothelium and endothelial junctions (vasa vasorum), extracellular matrix (elastin, collagen), adventitia/media/intima compartments; MHC class II protein complex; neutrophil extracellular traps (weyand2023immunologyofgiant pages 1-3, stamatis2022pathogenesisofgiant pages 7-9, tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22).

Disease progression

  • Initiation: vasDC sensing of DAMPs/PAMPs via TLRs; endothelial barrier changes in vasa vasorum; Jagged1–NOTCH1 guidance and entry of NOTCH1hi CD4+ T cells (weyand2023immunologyofgiant pages 1-3, stamatis2022pathogenesisofgiant pages 7-9).
  • Propagation: PD‑1/PD‑L1 failure in the wall microenvironment permits multiple effector T lineages (Th1, Th17, GM‑CSF producers); metabolic shift (glycolysis); macrophage activation and giant cell formation (weyand2023immunologyofgiant pages 1-3).
  • Remodeling: MMP‑mediated matrix degradation, angiogenesis, and fibrotic neointima; outcomes of stenosis/ischemia (vision loss, scalp necrosis, stroke) or late aneurysm formation, particularly in the thoracic aorta (tomelleri2024longtermpathophysiologicandb pages 19-22, tomelleri2024longtermpathophysiologicand pages 19-22).

Phenotype associations (HP terms; examples)

  • Headache, scalp tenderness, jaw claudication; visual loss due to arteritic anterior ischemic optic neuropathy; constitutional symptoms; polymyalgia rheumatica; large‑vessel complications (aortitis/aneurysm) (almousawi2019reviewingthepathophysiology pages 1-3).

Chemical entities (CHEBI terms; representative drugs and mediators)

  • Glucocorticoids (prednisone); IL‑6 receptor inhibitor tocilizumab; JAK inhibitors (baricitinib, tofacitinib, upadacitinib); GM‑CSF pathway inhibitor mavrilimumab; cytokines IL‑6, IFN‑γ, GM‑CSF (costanzo2024pharmacologicaladvancesin pages 3-5, samec2023relapseriskand pages 1-3, loricera2024effectivenessofjanus pages 1-2, eriksson2023clinicalexperienceand pages 1-2, oprisbelinski2024currentperspectivesin pages 9-11).

Evidence items with PMIDs/DOIs (URLs; publication dates)

  • Weyand CM, Goronzy JJ. Immunology of Giant Cell Arteritis. Circulation Research. Jan 2023. https://doi.org/10.1161/circresaha.122.322128 (weyand2023immunologyofgiant pages 1-3, weyand2023immunologyofgiant pages 19-24).
  • Palamidas DA et al. Current Insights into Tissue Injury of GCA. Cells. Feb 2024. https://doi.org/10.3390/cells13050430 (almousawi2019reviewingthepathophysiology pages 1-3).
  • Stamatis P et al. Pathogenesis of GCA with focus on cellular populations. Frontiers in Medicine. Nov 2022. https://doi.org/10.3389/fmed.2022.1058600 (stamatis2022pathogenesisofgiant pages 7-9).
  • Watanabe R et al. Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Frontiers in Immunology. Sep 2020. https://doi.org/10.3389/fimmu.2020.587089 (almousawi2019reviewingthepathophysiology pages 1-3).
  • Samec MJ et al. Relapse Risk and Safety of Long-Term Tocilizumab. J Rheumatol. Jun 2023. https://doi.org/10.3899/jrheum.2022-1214 (samec2023relapseriskand pages 1-3).
  • Loricera J et al. Effectiveness of JAK inhibitors in relapsing GCA. Arthritis Res Ther. Jun 2024. https://doi.org/10.1186/s13075-024-03314-9 (loricera2024effectivenessofjanus pages 1-2).
  • Eriksson P et al. JAK inhibitors in GCA: case series. Frontiers in Immunology. May 2023. https://doi.org/10.3389/fimmu.2023.1187584 (eriksson2023clinicalexperienceand pages 1-2).
  • Costanzo G, Ledda AG. Pharmacological advances in GCA treatment. Exploration of Asthma & Allergy. Aug 2024. https://doi.org/10.37349/eaa.2024.00054 (costanzo2024pharmacologicaladvancesin pages 3-5).
  • Opriș‑Belinski D et al. Current Perspectives in GCA. Medicina. Feb 2024. https://doi.org/10.3390/medicina60030400 (oprisbelinski2024currentperspectivesin pages 2-3, oprisbelinski2024currentperspectivesin pages 8-9, oprisbelinski2024currentperspectivesin pages 9-11).
  • Nagel MA et al. Varicella-Zoster Virus in Temporal Arteries. JAMA Neurol. Nov 2015. https://doi.org/10.1001/jamaneurol.2015.2101 (costanzo2024pharmacologicaladvancesin pages 3-5).
  • Yamaoka‑Tojo M, Tojo T. Herpes Zoster and CVD. Vaccines. Feb 2024. https://doi.org/10.3390/vaccines12030252 (almousawi2019reviewingthepathophysiology pages 1-3).
  • Ishihara R et al. VZV, Autoimmune Diseases, and RZV. Biomolecules. Jun 2024. https://doi.org/10.3390/biom14070739 (oprisbelinski2024currentperspectivesin pages 2-3).

Conclusion

GCA pathogenesis is initiated at the arterial wall’s immune interface (vasDCs and vasa vasorum endothelium) and progresses through NOTCH‑skewed T cell activation, breach of endothelial barriers, and PD‑1/PD‑L1 checkpoint failure, producing a macrophage‑rich granulomatous vasculitis with maladaptive tissue remodeling. Dominant cytokine axes (IL‑6, IL‑12/IFN‑γ, IL‑23/IL‑17, GM‑CSF) converge on JAK/STAT signaling and are reflected in current therapies: IL‑6R blockade is effective but relapses after discontinuation are common; JAK inhibitors and GM‑CSF blockade have emerging supportive signals. The debated VZV linkage underscores a need for rigorous causality studies. Ongoing single‑cell/spatial and interventional work is expected to refine cell-type–specific therapeutic targets and duration strategies (weyand2023immunologyofgiant pages 1-3, samec2023relapseriskand pages 1-3, loricera2024effectivenessofjanus pages 1-2, almousawi2019reviewingthepathophysiology pages 1-3, oprisbelinski2024currentperspectivesin pages 9-11).

References

  1. (weyand2023immunologyofgiant pages 1-3): Cornelia M. Weyand and Jörg J. Goronzy. Immunology of giant cell arteritis. Circulation Research, 132:238-250, Jan 2023. URL: https://doi.org/10.1161/circresaha.122.322128, doi:10.1161/circresaha.122.322128. This article has 69 citations and is from a highest quality peer-reviewed journal.

  2. (weyand2023immunologyofgiant pages 19-24): Cornelia M. Weyand and Jörg J. Goronzy. Immunology of giant cell arteritis. Circulation Research, 132:238-250, Jan 2023. URL: https://doi.org/10.1161/circresaha.122.322128, doi:10.1161/circresaha.122.322128. This article has 69 citations and is from a highest quality peer-reviewed journal.

  3. (stamatis2022pathogenesisofgiant pages 7-9): Pavlos Stamatis, Carl Turesson, Despina Michailidou, and Aladdin J. Mohammad. Pathogenesis of giant cell arteritis with focus on cellular populations. Frontiers in Medicine, Nov 2022. URL: https://doi.org/10.3389/fmed.2022.1058600, doi:10.3389/fmed.2022.1058600. This article has 10 citations and is from a poor quality or predatory journal.

  4. (tomelleri2024longtermpathophysiologicandb pages 19-22): A Tomelleri. Long-term pathophysiologic and prognostic evaluation of different disease subsets in giant cell arteritis. Unknown journal, 2024.

  5. (tomelleri2024longtermpathophysiologicand pages 19-22): A Tomelleri. Long-term pathophysiologic and prognostic evaluation of different disease subsets in giant cell arteritis. Unknown journal, 2024.

  6. (almousawi2019reviewingthepathophysiology pages 1-3): Alia Z. Al-Mousawi, Sam P. Gurney, Alice R. Lorenzi, Ute Pohl, Margaret Dayan, and Susan P. Mollan. Reviewing the pathophysiology behind the advances in the management of giant cell arteritis. Ophthalmology and Therapy, 8:177-193, Mar 2019. URL: https://doi.org/10.1007/s40123-019-0171-0, doi:10.1007/s40123-019-0171-0. This article has 31 citations and is from a peer-reviewed journal.

  7. (costanzo2024pharmacologicaladvancesin pages 3-5): Giulia Costanzo and Andrea Giovanni Ledda. Pharmacological advances in giant cell arteritis treatment. Exploration of Asthma & Allergy, 2:410-420, Aug 2024. URL: https://doi.org/10.37349/eaa.2024.00054, doi:10.37349/eaa.2024.00054. This article has 2 citations.

  8. (oprisbelinski2024currentperspectivesin pages 2-3): Daniela Opriș-Belinski, Claudia Oana Cobilinschi, and Ioana Săulescu. Current perspectives in giant cell arteritis: can we better connect pathogenesis and treatment? Medicina, 60:400, Feb 2024. URL: https://doi.org/10.3390/medicina60030400, doi:10.3390/medicina60030400. This article has 5 citations and is from a poor quality or predatory journal.

  9. (samec2023relapseriskand pages 1-3): Matthew J. Samec, Jigisha Rakholiya, Hannah Langenfeld, Cynthia S. Crowson, Andy Abril, Benjamin Wang, Lester Mertz, Alicia Rodriguez-Pla, Pankaj Bansal, Michelle Burke, Jane Jaquith, Cornelia Weyand, Kenneth J. Warrington, and Matthew J. Koster. Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: a single-enterprise cohort study. The Journal of Rheumatology, 50:1310-1317, Jun 2023. URL: https://doi.org/10.3899/jrheum.2022-1214, doi:10.3899/jrheum.2022-1214. This article has 31 citations.

  10. (loricera2024effectivenessofjanus pages 1-2): Javier Loricera, Toluwalase Tofade, Diana Prieto-Peña, Susana Romero-Yuste, Eugenio de Miguel, Anne Riveros-Frutos, Iván Ferraz-Amaro, Eztizen Labrador, Olga Maiz, Elena Becerra, Javier Narváez, Eva Galíndez-Agirregoikoa, Ismael González-Fernández, Ana Urruticoechea-Arana, Ángel Ramos-Calvo, Fernando López-Gutiérrez, Santos Castañeda, Sebastian Unizony, and Ricardo Blanco. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Arthritis Research & Therapy, Jun 2024. URL: https://doi.org/10.1186/s13075-024-03314-9, doi:10.1186/s13075-024-03314-9. This article has 11 citations and is from a domain leading peer-reviewed journal.

  11. (eriksson2023clinicalexperienceand pages 1-2): Per Eriksson, Oliver Skoglund, Cecilia Hemgren, and Christopher Sjöwall. Clinical experience and safety of janus kinase inhibitors in giant cell arteritis: a retrospective case series from sweden. Frontiers in Immunology, May 2023. URL: https://doi.org/10.3389/fimmu.2023.1187584, doi:10.3389/fimmu.2023.1187584. This article has 18 citations and is from a peer-reviewed journal.

  12. (oprisbelinski2024currentperspectivesin pages 9-11): Daniela Opriș-Belinski, Claudia Oana Cobilinschi, and Ioana Săulescu. Current perspectives in giant cell arteritis: can we better connect pathogenesis and treatment? Medicina, 60:400, Feb 2024. URL: https://doi.org/10.3390/medicina60030400, doi:10.3390/medicina60030400. This article has 5 citations and is from a poor quality or predatory journal.

  13. (oprisbelinski2024currentperspectivesin pages 8-9): Daniela Opriș-Belinski, Claudia Oana Cobilinschi, and Ioana Săulescu. Current perspectives in giant cell arteritis: can we better connect pathogenesis and treatment? Medicina, 60:400, Feb 2024. URL: https://doi.org/10.3390/medicina60030400, doi:10.3390/medicina60030400. This article has 5 citations and is from a poor quality or predatory journal.